The elevated 81% implied probability of no Encore Medical IPO before June 2026 stems primarily from the absence of a completed offering more than eight months after the company filed its S-1 registration statement in September 2025. The planned $15 million raise—3 million shares at a proposed $5 price—would produce a post-IPO market capitalization well below the higher outcome bands, consistent with the thin 4.5% odds assigned to a 55M+ close. Trader positioning also incorporates the firm’s continued reliance on ongoing FDA clinical trials for its cardiac septal occlusion devices, limited U.S. revenue visibility, and prevailing conditions in the small-cap healthcare IPO window, where debut timing has slipped for several comparable medtech issuers. Any acceleration would hinge on final pricing and NYSE American listing approval in the coming weeks.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于2026年6月前不上市 81%
4500万–5000万 7%
5500 万+ 4.5%
5,000万–5,500万 4.4%
$24,068 交易量
$24,068 交易量
2026-04-22
低于4500万
3%
4500万–5000万
7%
5,000万–5,500万
4%
5500 万+
5%
2026年6月前不上市
81%
2026年6月前不上市 81%
4500万–5000万 7%
5500 万+ 4.5%
5,000万–5,500万 4.4%
$24,068 交易量
$24,068 交易量
2026-04-22
低于4500万
$7,323 交易量
3%
4500万–5000万
$2,625 交易量
7%
5,000万–5,500万
$1,823 交易量
4%
5500 万+
$3,121 交易量
5%
2026年6月前不上市
$9,175 交易量
81%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.The elevated 81% implied probability of no Encore Medical IPO before June 2026 stems primarily from the absence of a completed offering more than eight months after the company filed its S-1 registration statement in September 2025. The planned $15 million raise—3 million shares at a proposed $5 price—would produce a post-IPO market capitalization well below the higher outcome bands, consistent with the thin 4.5% odds assigned to a 55M+ close. Trader positioning also incorporates the firm’s continued reliance on ongoing FDA clinical trials for its cardiac septal occlusion devices, limited U.S. revenue visibility, and prevailing conditions in the small-cap healthcare IPO window, where debut timing has slipped for several comparable medtech issuers. Any acceleration would hinge on final pricing and NYSE American listing approval in the coming weeks.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
市场开放时间： Apr 3, 2026, 7:59 PM ET
交易量
$24,068结束日期
2026-04-22市场开放时间
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.The elevated 81% implied probability of no Encore Medical IPO before June 2026 stems primarily from the absence of a completed offering more than eight months after the company filed its S-1 registration statement in September 2025. The planned $15 million raise—3 million shares at a proposed $5 price—would produce a post-IPO market capitalization well below the higher outcome bands, consistent with the thin 4.5% odds assigned to a 55M+ close. Trader positioning also incorporates the firm’s continued reliance on ongoing FDA clinical trials for its cardiac septal occlusion devices, limited U.S. revenue visibility, and prevailing conditions in the small-cap healthcare IPO window, where debut timing has slipped for several comparable medtech issuers. Any acceleration would hinge on final pricing and NYSE American listing approval in the coming weeks.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
交易量
$24,068结束日期
2026-04-22市场开放时间
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...The elevated 81% implied probability of no Encore Medical IPO before June 2026 stems primarily from the absence of a completed offering more than eight months after the company filed its S-1 registration statement in September 2025. The planned $15 million raise—3 million shares at a proposed $5 price—would produce a post-IPO market capitalization well below the higher outcome bands, consistent with the thin 4.5% odds assigned to a 55M+ close. Trader positioning also incorporates the firm’s continued reliance on ongoing FDA clinical trials for its cardiac septal occlusion devices, limited U.S. revenue visibility, and prevailing conditions in the small-cap healthcare IPO window, where debut timing has slipped for several comparable medtech issuers. Any acceleration would hinge on final pricing and NYSE American listing approval in the coming weeks.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题